EUVIMEDEUVIMED entdecken
Crossref

PYCR2 promotes growth and aerobic glycolysis in human liver cancer by regulating the AKT signaling pathway

Shaoyan Wang, Wenyan Yi, Zhenyu Xu, Minyu Shi

Biochemical and Biophysical Research Communications · 2023-11 · 680 · 15-24

DOI: 10.1016/j.bbrc.2023.09.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2023-11. Verfasst von Shaoyan Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, 200137, China. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) is the world's third most fatal cancer. Because metabolic rewiring is a hallmark of HCC, studies into the causes of aberrant glycolysis could provide insight into novel HCC therapeutic strategies. Pyrroline-5-carboxylate reductase 2 (PYCR2), a key enzyme of proline synthesis, has previously been found to play vital roles in various malignancies regarding amino acid metabolism and oxidative stress response. Our study investigated the mechanistic function of PYCR2 in HCC. We used Gene Expression Profiling Interactive Analysis to perform bioinformatics analysis of PYCR2 expression and survival in human HCC patients based on the Cancer Genome Atlas database. The function of PYCR2 in cell viability and glycolysis was assessed using CCK-8 and ECAR assays. Transducing shRNA or overexpression vectors into the HCC cell line altered the expression status of PYCR2. PYCR2 expression was validated using quantitative real-time PCR and Western blot. In mouse xenograft models, the role of PYCR2 in HCC tumor formation was confirmed. PYCR2 was overexpressed in human HCC tumor tissue and was associated with a poor prognosis. The functional assay revealed that silencing PYCR2 inhibited cell viability, glycolysis, and AKT activation. Furthermore, the xenograft experiment demonstrated that silencing PYCR2 significantly inhibited tumor growth and Ki67 expression. On the other hand, PYCR2 overexpression significantly promoted cell viability and glycolysis, which could be inhibited by either a glycolysis inhibitor or an AKT inhibitor, indicating that PYCR2 may function via glycolysis and the AKT pathway. Moreover, despite the overexpression of PYCR2 in vivo, treatment with a glycolysis inhibitor may considerably suppress tumor growth. Our findings suggest that PYCR2 may play an oncogenic role in HCC growth by promoting glycolysis and activating AKT, emphasizing PYCR2's clinical relevance in HCC management as a novel potential therapeutic target.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsCarcinoma, HepatocellularAnimalsMiceHumansProto-Oncogene Proteins c-aktSignal TransductionDisease Models, AnimalCell ProliferationGlycolysisCell Line, TumorGene Expression Regulation, NeoplasticPyrroline Carboxylate Reductasesdelta-1-Pyrroline-5-Carboxylate Reductase

Stichwörter der Autor:innen

AKT signaling pathwayGlycolysisHepatocellular carcinomaPYCR2

Substanzen

Proto-Oncogene Proteins c-aktPyrroline Carboxylate ReductasesPYCR2 protein, humandelta-1-Pyrroline-5-Carboxylate Reductase

Autor:innen und Institutionen

  • Department of Infectious Diseases, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, 200137, China.
  • Department of Emergency Internal Medicine, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, 200137, China.
  • Department of Infectious Diseases, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, 200137, China. Electronic address: shiminyu303@163.com.

Zitieren

APA

Wang, S., Yi, W., Xu, Z., & Shi, M. (2023). PYCR2 promotes growth and aerobic glycolysis in human liver cancer by regulating the AKT signaling pathway. Biochemical and Biophysical Research Communications, 680, 15-24. https://doi.org/10.1016/j.bbrc.2023.09.007

Vancouver

Wang S, Yi W, Xu Z, Shi M. PYCR2 promotes growth and aerobic glycolysis in human liver cancer by regulating the AKT signaling pathway. Biochemical and Biophysical Research Communications. 2023;680:15-24. doi:10.1016/j.bbrc.2023.09.007

BibTeX
@article{Wang2023,
  author = {Wang, Shaoyan and Yi, Wenyan and Xu, Zhenyu and Shi, Minyu},
  title = {PYCR2 promotes growth and aerobic glycolysis in human liver cancer by regulating the AKT signaling pathway},
  journal = {Biochemical and Biophysical Research Communications},
  year = {2023},
  volume = {680},
  pages = {15--24},
  doi = {10.1016/j.bbrc.2023.09.007}
}
Kostenlos starten →